ClinicalTrials.gg
RecruitingNCT05139056Updated Nov 4, 2026

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

A Phase 1 interventional study of Neural Stem Cells-expressing CRAd-S-pk7 and Resection in Currently Only Enrolling Glioblastoma Patients at First Recurrence, sponsored by City of Hope Medical Center. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Glioblastoma by City of Hope Medical Center — 6 open to participants now, 12 under way, none of them phase 3. Glioblastoma · City of Hope Medical Center.

Planned enrollment
3rd of 22
36 · median 19
Started
2023
the only one that year
Phase 1
20 of 23
4 open now
Primary completion
2028-02
later than 7 of 11 live
Registered
17th of 23
by date

Among the 23 studies in Glioblastoma by City of Hope Medical Center, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 20 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 17th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

6 of the 23 studies in Glioblastoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Glioblastoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine the recommended maximum tolerated number of cycles (MTC) of intracavitary (ICT) administered neural stem cell-expressing CRAd-S-pk7 (NSCCRAd-S-pk7) for phase II testing based on dose-limiting toxicities (DLTs), the overall toxicity profile, and activity in patients with recurrent high-grade glioma (HGG).

II. Describe and compare the weekly dosing schedule (Treatment Schedule 4) to an every 2 week dosing schedule (Treatment Schedule 4a) of intracerebrally administered NSC-CRAd-S-pk7 based on DLTs, the overall toxicity profile, and activity in patients with glioblastoma at first recurrence.

III. Determine the recommended phase 2 dose schedule based on the overall toxicity profile, and activity in patients with recurrent high grade gliomas

SECONDARY OBJECTIVES:

I. I. Assess for evidence of biologic activity (cytotoxicity and anti-tumor immune responses) in posttreatment tissue samples.

II. Assess for the presence of NSC and/or CRAd-S-pk7 in post-treatment tissue samples.

III. Assess for possible development of antibody and T cell responses to the NSCs and/or CRAd-S-pk7 in CSF and blood.

IV. Assess for evidence of possible migration of NSCs and/or CRAd-S-pk7 outside of the brain and if so, determine if viral shedding is occurring.

V. Determine the persistence and intracerebral distribution of the NSCs and/or CRAd-S-pk7 whenever permission is given to perform a brain autopsy on a study participant.

VI. Estimate the rates of disease response, progression-free survival at 6 months (PFS6mo) and overall survival at 9 months (OS9mo) for all study participants and separately for the cohorts of glioblastoma patients at first recurrence treated at the MTC administered once a week or every 2 weeks.

VII. Identify a molecular signature of vulnerability for predicting which glioma patients will benefit most from treatment with NSC-CRAd-S-pk7.

VIII. Describe and compare changes in immunosuppressive and immunostimulatory cytokines in CSF from study participants enrolled to Treatment Schedules 4 and 4a.

IX. Assess for the presence of exhausted T cell phenotypes in CSF samples and compare the degree of T cell exhaustion in study participants enrolled to Treatment Schedules 4 and 4a.

OUTLINE:

Patients undergo standard surgical resection, and during surgery the first dose of study agent is injected into the wall of the resection cavity. Patients then receive three additional doses every week or every two weeks via a catheter placed during surgery. A second catheter is placed in the cerebral ventricle to obtain serial samples of CSF for correlative studies. Two weeks after the last dose of study agent is administered, study participants undergo a second surgical procedure to remove the catheters and obtain post-treatment tissue samples for analysis.

FINANCIAL ASSISTANCE:

There is funding to help with the cost of transportation, lodging, and meals for participants who qualify for financial assistance.

03

Conditions studied

  • Currently Only Enrolling Glioblastoma Patients at First Recurrence

Browse trials for

Keywords

  • Recurrent glioblastoma, oncolytic virus, neural stem cells, first recurrence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be age >= 18 years
  • Patient has a performance status of >= 70%
  • Patient has a of >= 3 months

    • When determining the maximum tolerated number of treatment cycles (MTC): patient has a confirmed diagnosis of a grade 3 or 4 glioma (eg., glioblastoma, grade 4 astrocytoma, grade 3 astrocytoma, grade 3 oligodendroglioma). (This part of the study has been completed).
    • When enrolling to Treatment Schedules 4 and 4a: patient has glioblastoma at first recurrence.
  • Imaging studies show evidence of recurrent, supratentorial tumor(s).
  • Patient's high-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide
  • The patient must be in need of surgery for tumor resection
  • Based on the neurosurgeon's judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
  • (ANC) of >= 1000 cells/mm\^3
  • count >= 100,000 cells/mm\^3
  • Total =\< 2.0 mg/dl
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =\< 4 times the institutional
  • Serum creatinine =\< the institutional upper limit of normal
  • At least 2 weeks from taking the last dose of a targeted agent
  • At least 4 weeks from the last dose of bevacizumab For temozolomide, an interval of 23 days is required from the last dose administered if the patient was recently treated with adjuvant temozolomide, consisting of temozolomide daily for 5 days, repeated every 28 days.
  • At least 2 weeks from taking the last dose of a targeted agent.
  • At least 4 weeks from the last dose of bevacizumab.
  • All significant toxicities from previous anticancer therapy must have stabilized to a new baseline or resolved.
  • All participants must have the ability to understand and the willingness to sign a written .
  • The effects of this treatment on a developing fetus are unknown. Therefore, female patients of and sexually-active male patients or who are able to impregnate their partner, must agree to use an effective method of while participating in this study. Patients of childbearing potential must have a negative pregnancy test =\< 2 week prior to registration.

Exclusion criteria

Exclusion Criteria:

  • Patient has multi-focal disease.
  • Patient is receiving radiation, chemotherapy, or another agent.
  • Patient has had prior therapy with neural stem cells.
  • Patient has not recovered from any toxicity (> grade 1) of prior therapies, except alopecia.
  • Patient is unable to undergo a brain MRI.
  • Patient has chronic or active viral infections of the central nervous system (CNS).
  • Patient has a coagulopathy or bleeding disorder.
  • Patient has an uncontrolled illness including ongoing or active infection.
  • Patient has another active .
  • Patient is pregnant or breastfeeding.
  • A patient has a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Treatment (NSC-CRAd-S-pk7)

    Patients undergo standard surgical resection, and during surgery the first dose of study agent is injected into the wall of the resection cavity. Patients then receive three additional doses every week or every two weeks (depending on when they enroll in the study) via a catheter that was placed during surgery

    Biological: Neural Stem Cells-expressing CRAd-S-pk7 · Procedure: Resection

Interventions

  • BiologicalNeural Stem Cells-expressing CRAd-S-pk7

    Given intracerebrally

    Also known as: CRAd-S-pk7 loaded NSCs, NSC-CRAd-S-pk7, NSC-CRAd-S-pk7 Virotherapeutic, NSCs loaded with CRAd-S-pk7, SC-CRAd-Survivin-pk7

  • ProcedureResection

    Undergo surgical resection

    Also known as: Intracerebral administration of NSC-CRAd-S-pk7 via intracavitary catheter, Removal of CSF samples via a catheter placed in the lateral cerebral ventricle

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Assessed using the Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days post removal of Rickhams

  2. Progression-free survival (PFS)

    Will estimate the rate 90% confidence interval (CI) for PFS at 6 months and use Kaplan Meier methods to estimate median PFS for all study participants as well as for the cohorts of glioblastoma (GBM) participants at first recurrence who will be treated with 4 doses of NSC-CRAd-S-pk7 given once a week or every two weeks.

    Time frame: From the time of surgery to the event date of progression, assessed at 6 months]

Secondary outcomes

  1. Neural Stem Cells-expressing CRAd-S-pk7 (NSC-CRAd-S-pk7) immunogenicity

    Time frame: Up to 30 days post removal of Rickhams

  2. NSC-CRAd-S-pk7 migration within the brain

    Neural stem-cells and/or free viral particles will be assessed in samples of post-treatment tissue samples.

    Time frame: Up to 30 days post removal of Rickhams

  3. NSC-CRAd-S-pk7 migration outside the brain

    4\. Neural stem-cells and/or free viral particles will be assessed in samples of CSF, peripheral blood, urine, oral and rectal mucosa (via swabbing), and skin at the injection site (also via swabbing).

    Time frame: Up to 30 days post removal of Rickhams

  4. Disease response

    Response Assessment in Neuro-Oncology Criteria will be used to assess response on brain magnetic resonance imaging in all study participants who receive at least 80% of the planned doses of study treatment. Disease response will be similarly assessed for the cohorts of GBM participants at first recurrence who will be treated with 4 doses of NSC-CRAD-S-pk7 once a week or every two weeks.

    Time frame: Up to 2 years

  5. Overall survival (OS)

    Will estimate the rate 90% CI for OS at 9 months and use Kaplan Meier methods to estimate median OS for all study participants as well as for the cohorts of GBM participants at first recurrence who will be treated with 4 doses of NSC-CRAd-S-pk7 once a week or every two weeks.

    Time frame: From time of surgery to date of death, assessed at 9 months

  6. Changes in HSPG and survivin expression

    Changes in survivin expression by immunohistochemistry IHC in pre- and post-treatment tissue to see if there is a relationship with disease response.

    Time frame: Baseline up to 2 years

  7. Changes in immune cell populations

    Changes in immune cell populations in the tumor microenvironment in pre- and post-treatment tumor tissue samples will be assessed by Vectra Spectral Imaging.

    Time frame: Baseline up to 2 years

  8. Changes in tumor growth

    Develop a biomathematical model for predicting tumor response to study treatment.

    Time frame: Baseline up to 2 years

  9. Assessed using multiplex immunoassays in cerebrospinal fluid (CSF) samples and RNA-sequencing in CSF, peripheral blood, and tumor tissue samples.

    Time frame: Up to 30 days post removal of Rickhams

07

Study locations

2 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Feb 2028, 57 months after the start.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 57 months is above that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Aug 2027 → Feb 2028 and completion Aug 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Dec 1, 2021
StartActual
May 2, 2023
Primary completionEst.
Feb 7, 2028was Aug 2027
CompletionEst.
Feb 7, 2028was Aug 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 4, 2027→Feb 7, 2028
Nov 4, 2026
Study completion
Aug 4, 2027→Feb 7, 2028
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Aug 4, 2027→Feb 7, 2028
    Study completion Aug 4, 2027→Feb 7, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05139056
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
May 2, 2023
Primary completion
Feb 7, 2028 (estimated)
Completion
Feb 7, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Jana L Portnow, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion